AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma ...

Bruton's Tyrosine Kinase (BTK): An enzyme that plays a crucial role in the signaling pathways of B cells; inhibitors of BTK are used in the treatment of certain blood cancers. Progression-Free ...

8 In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis and adhesion. CALQUENCEhas been used to treat more than 85,000 patients ...

AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...

The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...

Recent years have witnessed notable progress in tailoring treatments for solid tumors using biomarkers. Nevertheless, identifying specific biomarkers for ...

Inhibitors of Bruton's tyrosine kinase (BTK), an intracellular signalling enzyme expressed in B cells and ... and therapeutic targets for smouldering disease activity, new pathways for remyelination ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitor selection in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) depends on key factors including prior therapy ...

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic ...